Menu ×


Epinephrine Market Analysis by Type (Epinephrine Prefilled Syringes, Epinephrine Auto-Injectors, Ampoules & Vials, and Others); by Application (Cardiac Arrest, Anaphylaxis, Superficial Bleeding, Respiratory Disorders, and Others); and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • Pfizer Inc. announced that it is in coordination with FDA to extend the expiration dates of certain lots of EpiPen 0.3 mg Auto-Injectors after reviewing the stability data. Pfizer works to stabilize the supply of these particular lots of products so that patients feel confident using them.
  • Teva Pharmaceuticals Industries Ltd. announced the accessibility of the FDA-approved generic version of EpiPen Jr 1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. Currently, the product is available in pharmacies nationwide.

Global Epinephrine Market Highlights Over 2023 - 2033

Base Year


Forecast Year




Base Year Market Size (2022)

 ~ USD 1 Billion

Forecast Year Market Size (2033)

~ USD 4 Billion

The global epinephrine market is estimated to garner a revenue of ~USD 4 billion by the end of 2033 by growing at a CAGR of ~12% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 1 billion in the year 2022. The growth of the market is primarily attributed to the worldwide growing prevalence of several allergic reactions, and neurological disorders. It is observed that, every year,


Get more information on this report: Request Sample PDF

Adrenaline, also known as epinephrine, is a hormone and neurotransmitter which is generated by the adrenal glands. Epinephrine is used as the first line of treatment to help reverse the effects of anaphylaxis. Individuals suffering from anaphylactic shock frequently use auto-injectors as they have the ease to be administered by non-medical personnel. The rising number of anaphylaxis occurrence is fueling up the growth of the market over the forecast period. For instance, anaphylaxis, a severe allergic reaction to food, is thought to cause nearly 91,000 emergency room visits annually in the United States.

Global Epinephrine Market: Growth Drivers and Challenges

Growth Drivers

  • Upsurge in Chronic Respiratory Disorders - Respiratory disorders refers to a class of pathogenic conditions such as COPD, and asthma, that affect respiration in living organisms. In higher organisms, respiration allows for gas exchange. In a gas exchange, the organism absorbs oxygen and exhales carbon dioxide. The respiratory tract, which comprises the alveoli, bronchi, bronchioles, pleura, pleural cavity, trachea, and the breathing muscles and nerves, is where respiratory disease develops itself. Therefore, global increase in respiratory disorders is leading the demand for the epinephrine. As per the World Health Organization (WHO), 3.23 million people died from chronic obstructive pulmonary disease (COPD), the third most common cause of mortality in the world in 2019.
  • Growing Occurrence of Several Types of Allergic Reactions - For instance, every year, more than 51 million individuals in the United State deal with various allergies. These allergic reactions are the region's sixth most common cause of chronic illness.
  • Escalation in Cardiac Arrests – It is observed that, in the United States, there are over 357,000 out-of-hospital cardiac arrests (OHCA) each year, with nearly 89% of them are life threatening.
  • Increasing Development in Auto Injectors – For instance, until now, nearly 81 auto injectors have been developed by more than 20 drug manufacturers. For use with auto injectors, about 49 medicines are created as combination products. Of them, disposable auto injectors make up nearly 61% of the total. Reusable auto injectors with various doses are being developed at a remarkable rate.
  • Increasing Healthcare Expenditure – As per the World Bank, in 2019, global healthcare expenditures expanded by 9.83%.


  • High Cost of Auto Injectors
  • Lack of Availability of Approved Medicines
  • Inadequate Reimbursement in Developing Nations

The global epinephrine market is segmented and analyzed for demand and supply by application into cardiac arrest, anaphylaxis, superficial bleeding, respiratory disorders and others. Out of these, the anaphylaxis segment is anticipated to hold the highest share over the forecast period owing to the development of technologically advanced products from the key players, and globally increasing prevalence of anaphylaxis in pediatrics as well as in adults. In a clinical study, it was observed that, the prevalence of anaphylaxis in children ranges from 1 to 762 per 100,000 person-years. The prevalence rate varied throughout continents; for example, while in Europe they ranged from 2.4 to 762 per 100,000 person-years to 0.8 to 70 in North America. Anaphylaxis incidence rate in the pediatric population ranged from 0.05% to 1.7% worldwide.

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Epinephrine Market Regional Synopsis

Regionally, the global epinephrine market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2033 backed by the escalating count of patients suffering from respiratory diseases such i.e., asthma, expanding population, rising awareness about allergies, and growing prevalence of cardiac arrests in the region. According to a health survey conducted between 2018 - 2020, in the United States the surge of asthma cases in young individuals aged 18+ years reached to 21,030,480 that denotes an 8.3% growth.


The global epinephrine market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global epinephrine market includes the following segments:

By Type

  • Epinephrine Prefilled Syringes
  • Epinephrine Auto-Injectors
  • Ampoules & Vials
  • Others

By Application

  • Cardiac Arrest
  • Anaphylaxis
  • Superficial Bleeding
  • Respiratory Disorders
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Top Featured Companies Dominating the Global Epinephrine Market
  • Teva Pharmaceuticals Industries Ltd.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Amneal Pharmaceuticals, Inc.
  • Adamis Pharmaceuticals Corporation
  • Antares Pharma, Inc.
  • Pfizer Inc.
  • kaleo, Inc.
  • ALK-Abelló A/S
  • Bausch Health Companies Inc.
  • Lincoln Medical Centre Ltd.
  • Abbott Laboratories



Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved